I would consider 40,000 the goal for f/y 2016 imo. At the time of the opening we could produce 120 patches per week, which as far as I am aware from follow up discussions is the current capacity. 120 patches x 52 weeks = 6240 (smaller patches) = $9.3m p/a. With capacity to scale up to 360 smaller patches per week (subject to staffing - in future) 360 patches x 52 weeks = 18720 = $28m p/a.
This is all providing that only the small patches are ordered as you can obviously produce less of the larger patches. To commission a clean room as I understand is a lengthy process and as far as I am aware it will not be a mirror of the first clean room but more than likely a preparation room to prepare the bovine material for processing. Therefore developing a production line which, as systems develop will exponentially increase production.
To achieve the above figures of takings between $9.3m p/a to $28m p/a in the first year of operation of the facility, from zero last year - will be a fantastic achievement, not to mention the possible partnering and funding opportunities IF phase 1 and 2 / or interim phs 2 are sucessful
- Forums
- ASX - By Stock
- AVR
- The Shed
The Shed, page-62
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$17.91 |
Change
0.000(0.00%) |
Mkt cap ! $344.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 150 | $18.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.80 | 3 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 150 | 18.000 |
1 | 681 | 17.900 |
2 | 451 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
Price($) | Vol. | No. |
---|---|---|
17.800 | 3 | 1 |
18.000 | 100 | 1 |
18.240 | 500 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
Last trade - 09.44am 16/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online